BioNexus Gene Lab Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by BioNexus Gene Lab Corp. on December 24, 2025. The Company is incorporated in Wyoming and trades on The Nasdaq Stock Market LLC under the symbol BGLC. It is classified as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Four proposals were submitted to a vote of security holders, all of which were approved:
- Proposal 1 (Election of Directors): Four nominees were elected. Su-Leng Tan Lee, Muhammad Azrul bin Abdul Hamid, and Chee Keong Yap each received 972,902.8 votes for. Jook Yuen Low received 971,641.8 votes for. Votes against ranged from 4,485.5 to 4,485.5, with abstentions between 300 and 1,561.
- Proposal 2 (2025 Equity Incentive Plan): Approved with 966,759.8 votes for, 10,628.5 votes against, and 300 abstentions.
- Proposal 3 (Ratification of Auditors): JP Centurion & Partners PLT was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote was 973,284.3 for, 3,402.5 against, and 1,001.5 abstentions.
- Proposal 4 (Adjournment): Approved with 966,489.3 votes for, 9,647.5 votes against, and 1,551.5 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirm the total number of shares outstanding to contextualize the voting percentages.
- Verify the specific terms and share limits of the newly approved 2025 Equity Incentive Plan.
- Review the full proxy statement for details on the background of the elected directors.
- Check subsequent filings for the Company's audited financial results for the fiscal year ending December 31, 2025.